The FDA has approved Tezspire (tezepelumab-ekko) for the add-on maintenance treatment of adult and pediatric patients aged 12 years and older with inadequately controlled chronic rhinosinusitis with ...
Approval based on WAYPOINT Phase III results demonstrating reduced nasal polyp severity and nasal congestion, near-elimination of the need for surgery and significantly reduced systematic ...
Oticara’s intranasal steroid cream met co-primary endpoints, demonstrating significant improvements in 4CSS and SNOT-22Single ...
Neurent Medical, a leader in non-surgical treatments for chronic rhinitis, today announced that UnitedHealthcare's Medicare Advantage policy has removed CPT 31242 posterior nasal nerve ablation using ...
The FDA approved tezepelumab-ekko (TEZSPIRE; AstraZeneca/Amgen) on Friday as an add-on maintenance treatment in patients aged ...
Discover how human nasal organoids reveal bacterial interactions in noses, influencing immune responses and health.
Amgen and AstraZeneca’s Tezspire (tezepelumab-ekko) gains FDA approval as an add-on maintenance therapy for patients aged 12 and older with inadequately controlled chronic rhinosinusitis with nasal ...
The first needle-free adrenaline treatment launches in the UK, validating non-invasive delivery with real-world data ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback